7-甲基-5,6,7,8-四氢咪唑并[1,2-a]吡嗪-2-羧酸乙酯 | 623564-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 7-甲基-5,6,7,8-四氢咪唑并[1,2-a]吡嗪-2-羧酸乙酯
• 英文名称: ethyl 7-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate
• 英文别名: ethyl 7-methyl-6,8-dihydro-5H-imidazo[1,2-a]pyrazine-2-carboxylate
• CAS: 623564-19-2
• 化学式: C₁₀H₁₅N₃O₂
• 分子量: 209.248
• InChiKey: DEQZHPHBXYMRRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  47.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  7-甲基-5,6,7,8-四氢咪唑并[1,2-a]吡嗪-2-羧酸乙酯 在 phosphate buffer 、 乙醚 、 二异丁基氢化铝 、 三乙胺 、 magnesium bromide 、 锌 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 反应 27.0h， 生成 (5R),(6Z)-6-(7-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-ylmethylene)-7-oxo-4-thia-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium salt
  参考文献：
  名称：

  Structure-Activity Relationship of 6-Methylidene Penems Bearing 6,5 Bicyclic Heterocycles as Broad-Spectrum β-Lactamase Inhibitors:  Evidence for 1,4-Thiazepine Intermediates with C7 R Stereochemistry by Computational Methods

  摘要：

  The design and synthesis of a series of 6-methylidene penems containing [6,5]-fused bicycles (thiophene, imidazole, or pyrazle-fused system) as novel class A, B, and C beta-lactamase inhibitors is described. These penems proved to be potent inhibitors of the TEM-1 (class A) and AmpC (class C) beta-lactamases and less so against the class B metallo-beta-lactamase CcrA. Their in vitro and in vivo activities in combination with piperacillin are discussed. On the basis of the crystallographic structures of a serine-bound reaction intermediate of 2 with SHV-1 (class A) and GC1 (class C) enzymes, compounds 14a-1 were designed and synthesized. Penems are proposed to form a seven-membered 1,4 thiazepine ring in both class A and C beta-lactamases. The interaction energy calculation for the enzyme-bound intermediates favor the formation of the C7 R enantiomer over the S enantiomer of the 1,4-thiazepine in both beta-lactamases, which is consistent with those obtained from the crystal structure of 2 with SHV-1 and GC1.

  DOI：

  10.1021/jm060021p
• 作为产物：
  描述：

  5,6,7,8-四氢咪唑并[1,2-a]吡嗪-2-甲酸乙酯 在 聚合甲醛 、 sodium cyanoborohydride 作用下， 以99.2%的产率得到7-甲基-5,6,7,8-四氢咪唑并[1,2-a]吡嗪-2-羧酸乙酯
  参考文献：
  名称：

  SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS

  摘要：

  揭示了一种取代苯丙烯基吡啶衍生物，其制备方法以及其作为PD-1/PD-L1抑制剂的用途。具体地，揭示了一种符合式(I)的化合物或其药用可接受的盐、立体异构体、溶剂合物或前药，以及其制备方法和用途。公式中每个基团的定义在描述和权利要求中详细说明。

  公开号：

  US20210386721A1

文献信息

• [EN] HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS HÉTÉRO-HALOGÉNO D'HISTONE DÉSACÉTYLASE
  申请人：RODIN THERAPEUTICS INC

  公开号：WO2017007756A1

  公开（公告）日：2017-01-12

  This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

  这项发明提供了抑制HDAC2的化合物。这些化合物（例如，符合式I、II或化合物100-128中的任何一种，或表2或3中的任何一种）可用于治疗、缓解或预防受试者的疾病，如神经系统疾病、记忆或认知功能障碍或损伤、消退学习障碍、真菌疾病或感染、炎症性疾病、血液疾病或肿瘤性疾病，或用于改善记忆或治疗、缓解或预防记忆丧失或损伤。
• SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS
  申请人：Gerlach Kai

  公开号：US20100099664A1

  公开（公告）日：2010-04-22

  The object of the present invention is novel substituted pyrrolidine amides of the general formula (I) in which D, L. E, G, J, M, L 1 , L 2 , R 4 , and R 5 are defined as in the specification, the tautomers, enantiomers, diastereomers, mixtures, and salts thereof, particularly physiologically tolerated salts with inorganic or organic acids or bases having valuable properties.

  本发明的对象是新颖的取代吡咯烷酰胺，其具有通式(I)，其中D、L、E、G、J、M、L1、L2、R4和R5如说明书所述定义，包括其互变异构体、对映异构体、非对映异构体、混合物以及盐，特别是具有宝贵性质的与无机或有机酸或碱的生理耐受盐。
• A Continuous Flow Strategy for the Facile Synthesis and Elaboration of Semi-Saturated Heterobicyclic Fragments
  作者：Nicola Luise、Eleanor W. Wyatt、Gary J. Tarver、Paul G. Wyatt

  DOI：10.1002/ejoc.201801684

  日期：2019.2.14

  Hydrogenation under continuous flow conditions was employed to deliver semi‐saturated fragments, presenting ideal physicochemical properties and characterized by key motifs for both their synthetic elaboration and binding to biological targets. Their facile functionalization, in continuous flow, represents a valid opportunity for the multi‐step synthesis of functionalized sp3‐rich fragments.

  在连续流动条件下进行氢化反应可得到半饱和片段，具有理想的理化特性，并具有合成修饰和与生物靶标结合的关键基序。它们连续不断地轻松进行功能化，为功能化富含sp 3的片段进行多步合成提供了一个有效的机会。
• Process for preparing 6-alkylidene penem derivatives
  申请人：Wyeth

  公开号：US20040132708A1

  公开（公告）日：2004-07-08

  The present invention provides a process of making compounds of formula I, which are useful for the treatment of bacterial infection or disease. 1

  本发明提供了一种制备式I化合物的方法，该化合物对治疗细菌感染或疾病有用。
• Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors
  申请人：Mansour Suhayl Tarek

  公开号：US20060276445A1

  公开（公告）日：2006-12-07

  This invention relates to certain bicyclic 6-alkylidene penems which act as a inhibitor of class-D enzymes. β-Lactamases hydrolyze β-lactam antibiotics, and as such serve as the primary cause of bacterial resistance. The compounds of the present invention when combined with β-lactam antibiotics will provide an effective treatment against life threatening bacterial infections. In accordance with the present invention there are provided compounds of general formula I or a pharmaceutically acceptable salt or in vivo hydrolyzable ester R 5 thereof: wherein: One of A and B denotes hydrogen and the other an optionally substituted fused bicyclic heteroaryl group; and X═O or S.

  这项发明涉及某些具有双环6-烷基亚烯基青霉素结构的化合物，其作为D类酶的抑制剂。β-内酰胺酶水解β-内酰胺类抗生素，因此是细菌耐药的主要原因。本发明的化合物与β-内酰胺类抗生素结合后，将提供一种有效的治疗方法，用于治疗威胁生命的细菌感染。根据本发明，提供了一般式I的化合物，或其药学上可接受的盐或体内可水解的酯R5：其中：A和B中的一个表示氢，另一个表示可选择取代的融合双环杂环芳基团；X＝O或S。